OAKVILLE, ON, Feb. 21, 2018 /CNW/ - Concordia International
Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an
international specialty pharmaceutical company focused on becoming
a leader in European specialty, off-patent medicines, today
announced it intends to issue its fourth quarter and year-end 2017
financial results via press release before market open on
Thursday, March 8, 2018.
The Company will subsequently hold a conference call that same
day, Thursday, March 8, 2018, at
8:30 a.m. ET hosted by Mr.
Allan Oberman, Chief Executive
Officer, and other senior management. A question-and-answer session
will follow the corporate update.
CONFERENCE CALL
DETAILS
|
|
DATE:
|
Thursday, March 8,
2018
|
TIME:
|
8:30 a.m.
ET
|
DIAL-IN
NUMBER:
|
(647) 427-7450 or
(888) 231-8191
|
TAPED
REPLAY:
|
(416) 849-0833 or
(855) 859-2056
|
REFERENCE
NUMBER:
|
9289998
|
This call is being webcast and can be accessed by going to:
http://event.on24.com/r.htm?e=1602683&s=1&k=4B1F2F5D6D72A7BEA92E8C9BB0354437
An archived replay of the webcast will be available by clicking
the link above.
About Concordia
Concordia is an international
specialty pharmaceutical company with a diversified portfolio of
more than 200 patented and off-patent products, and sales in more
than 90 countries. Going forward, the Company is focused on
becoming a leader in European specialty, off-patent medicines.
Concordia operates out of facilities in Oakville, Ontario and, through its
subsidiaries, operates out of facilities in Bridgetown, Barbados; London, England and Mumbai, India.
Notice regarding forward-looking statements and
information:
This news release includes forward‐looking
statements within the meaning of the United States Private
Securities Litigation Reform Act of 1995 and forward‐looking
information within the meaning of Canadian securities laws,
regarding Concordia and its business, which may include, but are
not limited to, statements with respect to the release date of
Concordia's financial results and Concordia's focus on becoming a
leader in European specialty, off-patent medicines. The
forward‐looking events and circumstances discussed in this news
release may not occur by certain dates or at all and could differ
materially as a result of known and unknown risk factors and
uncertainties affecting Concordia, including risks associated with
Concordia's securities, increased indebtedness and leverage,
Concordia's growth, risks associated with the use of Concordia's
products, the inability to generate cash flows, revenues and/or
stable margins, the inability to repay debt and/or satisfy future
obligations, risks associated with a delay in releasing Concordia's
financial statements (which could result in a default under
Concordia's debt agreements and a violation of applicable laws),
Concordia's inability to execute and implement its growth strategy,
Concordia's inability to become a leader in European specialty, off
patent medicines, Concordia's outstanding debt, risks associated
with the geographic markets in which Concordia operates and/or
distributes its products, risks associated with distribution
agreements, the pharmaceutical industry and the regulation thereof,
regulatory investigations, the failure to comply with applicable
laws, economic factors, market conditions, risks associated with
growth and competition, the failure to obtain regulatory approvals,
the equity and debt markets generally, general economic and stock
market conditions, risks associated with fluctuations in exchange
rates (including, without limitation, fluctuations in currencies),
political risks (including changes to political conditions), risks
associated with the United
Kingdom's exit from the European Union (including, without
limitation, risks associated with regulatory changes in the
pharmaceutical industry, changes in cross‐border tariff and cost
structures and the loss of access to the European Union global
trade markets), risks related to patent infringement actions, the
loss of intellectual property rights, risks and uncertainties
detailed from time to time in Concordia's filings with the
Securities and Exchange Commission and the Canadian Securities
Administrators, and many other factors beyond the control of
Concordia. Although Concordia has attempted to identify important
factors that could cause actual actions, events or results to
differ materially from those described in forward‐looking
statements and information, there may be other factors that cause
actions, events or results to differ from those anticipated,
estimated or intended. No forward‐looking statement or information
can be guaranteed. Except as required by applicable securities
laws, forward‐looking statements and information speak only as of
the date on which they are made and Concordia undertakes no
obligation to publicly update or revise any forward‐looking
statement or information, whether as a result of new information,
future events, or otherwise.
SOURCE Concordia International Corp.